drugset
drugset / Trial / NCT06868849

A Study of JMT203 in Patients With Cancer Cachexia

NCT06868849 ↗

Phase 1/2 Recruiting 307 enrolled Shanghai JMT-Bio Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

A Phase Ia/II, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of JMT203 in Patients with Cancer Cachexia

Timeline

Start
2024-05-15
Primary completion
2027-08-14
Completion
2029-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject JMT203 Monoclonal antibody 50 mg Subcutaneous
Subject JMT203 Monoclonal antibody 150 mg Subcutaneous

Indications

colorectal cancer malignant pancreatic neoplasm non-small cell lung carcinoma pancreatic exocrine neoplasm